Skip to main
KZR
KZR logo

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences Inc. has a promising outlook due to the potential monetization of its lead candidate, zetomipzomib, through strategic business development opportunities, particularly in the underserved area of autoimmune hepatitis (AIH). The company may benefit from the FDA's decision to allow patients to complete the Phase 2a PORTOLA trial, indicating a supportive regulatory environment that could lead to further data emergence and advancements in treatment for AIH. Additionally, the company’s focus on unmet medical needs in both autoimmunity and cancer positions it well for growth and valuation enhancements, especially if its other programs show positive developments.

Bears say

Kezar Life Sciences Inc. is projected to experience a significant financial burden, with a forecasted full-year 2024 net loss of $2.02 per share, reflecting continued operational challenges. The company recorded a 3Q24 net loss of $2.78 per share, which was substantially wider than previous estimates and highlights difficulties in managing expenses during a critical phase of development. Additionally, the board's rejection of a cash acquisition offer suggests a strategic misalignment and concerns regarding the company's valuation, further contributing to a negative outlook on the stock.

KZR has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Buy based on their latest research and market trends.

According to 4 analysts, KZR has a Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.